Malcolm A. S. Moore is an Emeritus Member of the Cell Biology Program in the Sloan Kettering Institute. Dr. Moore spent his career studying the factors that control the differentiation of hematopoietic progenitor cells into mature cells, with the goal of applying these insights to the treatment of cancer.
He is perhaps best known for his work leading to the development of the drug filgrastim. In 1984, he and Karl Welte, a member of his lab, isolated the protein in human cells that stimulates new blood cell growth. The protein is called granulocyte colony stimulating factor (G-CSF). Filgrastim is a recombinant version of G-CSF that helps patients suffering from neutropenia (low white blood cell counts), often as the result of chemotherapy. Over 3 million people, most of them with cancer, have received the drug, which is marketed by Amgen under the brand names Neupogen® and Neulasta®.
Dr. Moore is the recipient of numerous awards, including the William B. Coley Award for Basic and Tumor Immunology, the Hope Funds Award of Excellence in Basic Research, a Lifetime Achievement Award from the Cancer Research and Treatment Fund, and the C. Chester Stock Award. His discovery of G-CSF was named a “Major Cancer Milestone” by ASCO.
Dr. Moore received his doctorate in 1967 from the University of Oxford. In 1965, he was appointed a Prize Fellow at Magdalen College, Oxford. He was a Queen Elizabeth II Visiting Fellow (1967-1969) and Senior Research Scientist and Head of the Laboratory of Developmental Biology (1970-1974) at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia. In 1974, he moved to MSK where he held the Enid A. Haupt Chair of Cell Biology.
View a full listing of Malcolm A. S. Moore’s journal articles.